[1]郭伟,刘杰.紫杉醇载药器械是否增加下肢血运重建的远期全因死亡?——更多证据仍在路上[J].第三军医大学学报,2019,41(24):2370-2374.
 GUO Wei,LIU Jie.Is paclitaxel-coated device causing mortality for lower-extremity peripheral artery disease?——More evidence is on the way[J].J Third Mil Med Univ,2019,41(24):2370-2374.
点击复制

紫杉醇载药器械是否增加下肢血运重建的远期全因死亡?
——更多证据仍在路上
(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第24期
页码:
2370-2374
栏目:
专题报道
出版日期:
2019-12-31

文章信息/Info

Title:
Is paclitaxel-coated device causing mortality for lower-extremity peripheral artery disease?——More evidence is on the way
作者:
郭伟刘杰
解放军总医院血管外科,全军血管外科中心
Author(s):
GUO Wei LIU Jie

Department of Vascular and Endovascular Surgery, Center for Vascular Surgery, Chinese PLA General Hospital, Beijing, 100039, China

关键词:
紫杉醇载药器械下肢动脉硬化闭塞症全因病死率循证医学
Keywords:
paclitaxel-coated devices lower-extremity peripheral artery disease all-cause mortality evidence-based medicine
分类号:
R654.3;R608
文献标志码:
A
摘要:

紫杉醇载药物器械在治疗下肢动脉硬化闭塞症方面得到了越来越多的应用。最近一项包含28项随机对照研究的Meta分析显示,紫杉醇载药物器械增加远期全因死亡,然而更多的研究显示此结果具有很大的争议。本文解读了Meta分析和远期4项随机对照研究的结果,探讨聚焦于此问题的最新证据;并根据本中心的临床数据提供了应用紫衫醇载器械和采用以患者为中心的综合治疗建议。由于缺乏长期随机对照试验数据和大样本真实世界长期数据,目前将紫衫醇载器械和全因死亡联系起来仍不成熟,未来需要提供随机对照试验和大样本真实世界研究的长期治疗证据。

Abstract:

More and more paclitaxel-coated devices are used for the treatment of lower-extremity peripheral artery disease (LE-PAD). A recent meta-analysis containing 28 randomized controlled trials (RCTs) reported an increased risk of all-cause mortality in the paclitaxel-coated devices’group. However, more studies showed this result was controversial. In this article, we further analyze the meta-analysis report and 4 other RCTs with long-term outcomes, and also disscuss the most recent new evidence concerning paclitaxel-coated devices and mortality. We then provide a perspective on how to use paclitaxel-coated devices for LE-PAD and make patient-centered decision. In a word, due to the lack of long-term RCTs data and large sample real-world long-term data, it is quite immature to link the paclitaxel-coated devices with all-cause mortality. In future, long-term treatment evidence of RCTs and large sample real-world researches is needed.

参考文献/References:

[1]ROCHA-SINGH K J, JAFF M R, CRABTREE T R, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease[J]. Catheter Cardiovasc Interv, 2007, 69(6): 910-919. DOI: 10.1002/ccd.21104.
[2]KAYSSI A, AL-ATASSI T, OREOPOULOS G, et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs[J]. Cochrane Database Syst Rev, 2016(8): CD011319. DOI: 10.1002/14651858.CD011319.pub2.
[3]GIACOPPO D, CASSESE S, HARADA Y, et al. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials[J]. JACC Cardiovasc Interv, 2016, 9(16): 1731-1742. DOI: 10.1016/j.jcin.2016.06.008.
[4]KATSANOS K, SPILIOPOULOS S, KITROU P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: A systematic review and meta-analysis of randomized controlled trials[J]. J Am Heart Assoc, 2018, 7(24): e011245. DOI: 10.1161/JAHA.118.011245.
[5]SECEMSKY E A, KUNDI, WEINBERG I, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices[J]. JAMA Cardiol, 2019, 4(4): 332-340. DOI: 10.1001/jamacardio.2019.0325.
[6]SCHNEIDER P A, LAIRD J R, DOROS G, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon[J]. J Vasc Surg, 2019, 70(3): 1007. DOI: 10.1016/j.jvs.2019.06.094.
[7]BONASSI S. Letter by Bonassi regarding article, “Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: A systematic review and meta-analysis of randomized controlled trials”[J]. J Am Heart Assoc, 2019, 8(10): e012315. DOI: 10.1161/JAHA.119.012315.
[8]TEPE G, SCHNORR B, ALBRECHT T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial[J]. JACC Cardiovasc Interv, 2015, 8(1 Pt A): 102-108. DOI: 10.1016/j.jcin.2014.07.023.
[9]DAKE M D, ANSEL G M, JAFF M R, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial[J]. Circulation, 2016, 133(15): 1472-1483; discussion 1483. DOI: 10.1161/CIRCULATIONAHA.115.016900.
[10]Correction to: Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery 5-year results of the zilver PTX randomized trial[J]. Circulation, 2019, 139(8): e42. DOI: 10.1161/CIR.0000000000000657.
[11]SCHNEIDER P A, LAIRD J R, TEPE G, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial[J]. Circ Cardiovasc Interv, 2018, 11(1): e005891. DOI: 10.1161/CIRCINTERVENTIONS.117.005891.
[12]XU Y L, JIA X, ZHANG J W, et al. Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of 200 Chinese patients with severe femoropopliteal lesions: 24-month results of AcoArt I[J]. JACC Cardiovasc Interv, 2018, 11(23): 2347-2353. DOI: 10.1016/j.jcin.2018.07.041.
[13]JIA X, ZHANG J W, ZHUANG B X, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial[J]. JACC Cardiovasc Interv, 2016, 9(18): 1941-1949. DOI: 10.1016/j.jcin.2016.06.055.
[14]BECKMAN J A, WHITE C J. Don’t do something!: Just stand there[J]. J Am Coll Cardiol, 2019, 73(20): 2564-2566. DOI: 10.1016/j.jacc.2019.01.078.
[15]SWAMINATHAN R V, JONES W S, PATEL M R. Is paclitaxel causing mortality during lower-extremity revascularization?[J]. J Am Heart Assoc, 2019, 8(10): e012523. DOI: 10.1161/JAHA.119.012523.

更新日期/Last Update: 2019-12-17